Curis, Genentech stop co-development of basal cell carcinoma drug

By Lisa Kerner

Charlotte, N.C., Sept. 1 - Curis, Inc. announced it will no longer co-develop the basal cell carcinoma drug candidate with Genentech. The two companies formed a collaboration agreement in 2003, but recently halted enrollment in their phase 1 clinical trial.

The companies said there were no safety concerns; however, recent data from the trial suggests the topical treatment did not adequately penetrate human skin.

Genentech is now solely responsible for all future costs and development decisions.

Curis, based in Cambridge, Mass., has incurred roughly $8.4 million in co-development costs through June 30. The company is still eligible for milestone and royalty payments.

The companies will continue to conduct research in a systemic Hedgehog antagonist program for the treatment of solid tumor cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.